We've got news for you.

Register on BusinessLIVE at no cost to receive newsletters, read exclusive articles & more.
Register now

Generic drug maker Aspen Pharmacare, which faces a probe by the Competition Commission over the price of some of its cancer drugs, has kept its South African price hikes within the limits set by the health department, an analysis by Business Day shows. The local scenario is in sharp contrast to Europe, where Aspen is being investigated by competition authorities for implementing steep price hikes on the same drugs. The South African Competition Commission announced last Tuesday that it was launching an investigation into Aspen, Roche and Pfizer over the price of their cancer drugs. The Aspen drugs in question are Leukeran, Alkeran and Myleran, which were in a portfolio of off-patent drugs it acquired from GlaxoSmithKline in December 2009.

BL Premium

This article is reserved for our subscribers.

A subscription helps you enjoy the best of our business content every day along with benefits such as articles from our international business news partners; ProfileData financial data; and digital access to the Sunday Times and Sunday Times Daily.

Already subscribed? Simply sign in below.

Questions or problems? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now